All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this interview, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses practice-changing abstracts in the field of graft-versus-host disease that were presented during ASH 2019.
Mohamad Mohty talks about the benefits of stem cell transplantations and explains that it comes at a cost of complications such as graft-versus-host disease. He also discusses different prophylaxis regimens that are offered to patients and how that affects patient responses. He talks about the success of post-transplant cyclophosphamide in the haploidentical setting and questions its efficacy if it were to be translated into the identical sibling/unrelated setting. He also discusses the anticipated results of the HOVON trial. He concludes by discussing novel interventions such as the use of fecal microbiota transplant.
Practice-changing abstracts for GvHD from ASH 2019
Subscribe to get the best content related to GvHD delivered to your inbox